ANDA 65262, held by Teva. Ceftriaxone Sodium.
As of Nov 15, 2026, ANDA 65262 (Ceftriaxone), held by Teva, was first approved by FDA on Jun 29, 2006, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2006 | Original application | Approved |
| CeftriaxoneEQ 1GM BASE/VIAL · injectable;intramuscular, intravenous | Ceftriaxone Sodium | Discontinued |
| CeftriaxoneEQ 2GM BASE/VIAL · injectable;intramuscular, intravenous | Ceftriaxone Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
